Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5919_Библиотеки_им_академика_М_И_Перельмана.pdf
Drug Delivery to the Respiratory System: Novel Approaches and Therapeutics 319
Furthermore, this methodology provides a protective mechanism
for pH-sensitive drugs, shielding them from degradation as they
transit through diverse physiological environments. Collectively,
these benefits contribute to improved drug efficacy and safety
profiles in therapeutic interventions.
However, the challenges of this approach include the complexity of designing systems with appropriate pH sensitivity and the
potential for variability in local pH conditions among patients or
disease states.
6.3 Magnetic FieldGuided Delivery
Magnetic field-guided delivery is an innovative approach that combines nanotechnology with external magnetic fields to direct drugs
to specific lung areas [63]. This method offers a unique opportunity for the spatial control of drug delivery, potentially improving
therapeutic outcomes while minimizing off-target effects.
The core component of this strategy involves the utilization of
magnetic nanoparticles (MNPs), primarily composed of iron oxide
(e.g., magnetite or maghemite), owing to their biocompatibility
and superparamagnetic properties [
64]. MNPs are either
incorporated with pharmaceutical agents or function as constituents of more intricate drug delivery systems, such as liposomes or
polymeric nanoparticles. The magnetic field-guided delivery process encompasses several stages: drug incorporation, administration, magnetic guidance, retention, and drug release. The
intensity and duration of the applied magnetic field can be modulated to optimize drug targeting and retention with advanced configurations employing multiple magnets or electromagnetic systems
to generate complex field patterns and achieve precise targeting.
Magnetic field-guided delivery presents several advantages, including non-invasive spatial control of drug distribution, potential for
deep tissue targeting within the pulmonary system, reduced systemic drug exposure, possibility of repeated treatments without
additional invasive procedures, and integration with imaging techniques for theranostic applications [
65, 66].
However
, this
approach faces challenges such as limited penetration depth of
magnetic fields, potential for MNP aggregation, requirement for
specialized equipment and trained personnel, and complexity in
scaling up the production of stable, uniform magnetic drug carriers
67, 68].
[
Ongoing r
esearch i
n this field is focused on developing more
powerful and precisely controllable magnetic systems, improving
the stability and biocompatibility of magnetic carriers, and exploring their combination with other targeting strategies to enhance
their efficacy.
These targeted
drug delivery strategies represent significant
advances in pulmonary therapy. Each approach has unique advantages and presents distinct challenges. As research progresses, it is
320 Pabbathi Shivakumar et al.
likely that combinations of these strategies or entirely new
approaches will emerge, further revolutionizing the landscape of
targeted drug delivery to the lungs.
7 Emerging Therapeutics for Respiratory Diseases
Gene therapy for pulmonary diseases uses diverse vector systems to
deliver therapeutic genes to target cells [
ing adeno-associated viruses (AAVs), lentiviruses, and adenoviruses, are frequently employed owing to their efficacy in cell
transduction. AAVs are preferred for pulmonary applications
because of their low immunogenicity and capacity for long-term
gene expression [
and polymer-based systems, offer enhanced safety profiles and targeted delivery capabilities [71]. Physical methods, including electroporation and sonoporation, can facilitate localized gene transfer
[72]. Nevertheless, gene therapy for lung diseases presents several
challenges, including overcoming mucus barriers in the airways,
achieving sustained gene expression, and targeting specific cell
types within the pulmonary system [
vors are aimed at addressing these obstacles and enhancing the
efficacy of pulmonary gene therapy.
siRNA a
tools for modulating gene expression in respiratory diseases. siRNA
comprises double-stranded RNA molecules that induce mRNA
degradation, whereas antisense oligonucleotides are singlestranded DNA/RNA molecules that bind to the target mRNA,
thereby inhibiting translation or inducing degradation [
ous delivery strategies have been developed to enhance the efficacy
of these molecules, including inhalation for direct lung delivery,
conjugation with cell-penetrating peptides to improve cellular
uptake, and nanoparticle formulations to protect nucleic acids
from degradation [
potential in targeting inflammatory mediators in asthma and
chronic obstructive pulmonary disease (COPD), silencing oncogenes in pulmonary malignancies, and modulating host-pathogen
interactions in respiratory infections [
Cell-based therapies
cell types, including mesenchymal stem cells (MSCs) with antiinflammatory and immunomodulatory properties, induced pluripotent stem cells (iPSCs) for generating patient-specific lung cells,
and lung-resident progenitor cells that promote endogenous repair
mechanisms [
mechanisms, such as paracrine effects involving the secretion of
growth factors and anti-inflammatory molecules, cell replacement
through differentiation into functional pulmonary cell types, and
immunomodulation by regulating inflammatory responses.
70]. Non-viral vectors, such as lipid nanoparticles
nd a
ntisense oligonucleotides (ASOs) are sophisticated
75]
77, 78]. These therapies operate through multiple
hese approaches have demonstrated
. T
for lung diseases encompass diverse stem
69]. Viral vectors, includ-
73]. Ongoing research endea-
74]. Vari-
76].
Drug Delivery to the Respiratory System: Novel Approaches and Therapeutics 321
Applications of cell-based therapies include the treatment of
acute respiratory distress syndrome (ARDS) by attenuating inflammation and promoting tissue repair, reversal of fibrotic changes,
restoration of pulmonary function in pulmonary fibrosis, and the
development of personalized therapeutic approaches for cystic
fibrosis using gene-corrected stem cells.
However, several challenges persist in the field, including optimization of cell delivery and engraftment in the pulmonary system,
enhancement of long-term survival and function of transplanted
cells, and development of combination therapies that integrate
gene therapy and cell-based approaches. Addressing these challenges is crucial for advancing cell-based therapies for lung diseases.
8 Novel Formulations for Improved Drug Efficacy
In pharmaceutical research, innovative drug formulations are being
developed to enhance therapeutic efficacy by addressing key challenges, such as poor solubility, limited bioavailability, and adverse
effects. Researchers are employing advanced technologies and
materials to create sophisticated delivery systems that optimize
drug release, improve targeting precision, and enhance patient
compliance
8.1 ControlledRelease Formulations
Controlled-release formulations for pulmonary drug delivery
encompass diverse, innovative approaches. Polymeric microparticles, specifically those fabricated from biodegradable poly(lactic-coglycolic acid) (PLGA), encapsulate therapeutic agents for sustained
release over extended durations, maintaining therapeutic concentrations while concurrently reducing dosing frequency and adverse
effects [
79, 80]. Liposomes, phospholipid vesicles capable of
entrapping both hydrophilic and hydrophobic compounds, offer
prolonged release profiles and enhanced lung retention [
81].
Nanocarriers, including solid lipid nanoparticles and dendrimers, facilitate improved lung deposition and drug solubility, while providing
protection against enzymatic degradation [
82, 83]. In situ forming
gels utilize temperature- or pH-responsive polymers that generate a
depot for sustained drug release upon inhalation, thereby extending the residence time within the pulmonary environment.
Mucoadhesive systems employing polymers, such as chitosan,
adhere to lung mucus, thereby increasing drug contact time and
84].
absorption [
These formulations can be further optimized by
incorporating enzyme inhibitors or permeation enhancers to
enhance drug bioavailability, thereby collectively advancing the
field of pulmonary drug delivery.
322 Pabbathi Shivakumar et al.
8.2 Combination Therapies
Advancements in pulmonary drug deliver y have led to innovative
strategies for the co-administration of multiple therapeutic agents
into the lungs. These approaches aim to enhance efficacy, improve
adherence, and optimize delivery under complex respiratory
conditions [
85].
Fixed-dose combinations, nanoparticle-based co-delivery systems, layer-by-layer assembly techniques, dual-action prodrugs,
and complementary formulations represent innovative approaches
for multi-drug delivery in inhaled therapeutics. These strategies
offer distinct advantages, such as simplifying administration,
enhancing patient adherence, and improving therapeutic outcomes
for complex respiratory diseases. Fixed-dose combinations
co-formulate multiple drugs in a single inhaler, whereas
nanoparticle-based systems encapsulate drugs to achieve synergistic
effects and targeted delivery [
86]. Layer-by-layer assembly enables
tailored release profiles through sequential drug-layer deposition,
and dual-action prodrugs release two active compounds upon
enzymatic cleavage in the lungs [
87]. Complementary formulations
optimize lung deposition and absorption by combining drugs with
different physicochemical properties. Each approach addresses specific challenges in inhaled drug delivery, potentially revolutionizing
the treatment of respiratory conditions by enhancing efficacy,
patient compliance, and overall therapeutic outcomes.
8.3 Prodrug Approaches
Prodrug strategies offer promising solutions for pulmonary drug
delivery challenges by modifying the physicochemical properties of
drugs to enhance their absorption, distribution, and efficacy in the
lungs [
88]. This approach aims to optimize drug performance in
pulmonary applications, potentially improving treatments for respiratory diseases.
1. Ester Prodrugs: These formulations improve lipophilicity and
membrane permeability, enhancing cellular uptake and bioavailability. By converting polar functional groups into esters,
the lipophilicity of drugs can be increased, facilitating their
passage through cell membranes [
89]. Once inside the cell,
esterases cleave the prodrug and release the active compound.
This approach is particularly useful for improving the delivery
of hydrophilic drugs with poor membrane permeability.
2.
Phosphate Prodr
ugs: Increased water solubility facilitates
improved dissolution and absorption in the lung fluid. Phosphate groups are added to poorly water-soluble drugs to
enhance their aqueous solubility. In the lung environment,
phosphatases cleave phosphate groups to release the parent
drug. This strategy is beneficial for drugs with limited solubility
in lung fluid because it can improve their dissolution and
subsequent absorption [
90].
Drug Delivery to the Respiratory System: Novel Approaches and Therapeutics 323
3. Enzyme-Activated Prodrugs: Utilization of lung-specific
enzymes enables site-specific drug activation and reduces systemic side effects. These prodrugs are designed to be activated
by enzymes that are predominantly expressed in lung tissues
91]. This approach allows targeted drug release in the lungs
[
while minimizing activation and potential side effects in other
tissues. Enzyme-activated prodrugs can improve the therapeutic index of drugs by concentrating their activity at the desired
site of action.
4. PEGylation: Attachment of polyethylene glycol chains
increases drug stability and circulation time. PEGylation
involves covalent attachment of polyethylene glycol (PEG)
molecules to drugs or drug carriers. In pulmonary delivery,
PEGylation can enhance the stability of drugs in lung fluids,
reduce immunogenicity, and prolong their retention in the
lungs [
and peptide drugs that are susceptible to rapid clearance or
degradation.
5. Amino Acid Conjugates: These formulations enhance drug
stability and target-specific transporters in lung epithelial cells
for improved absorption [93]. By conjugating drugs with
amino acids, it is possible to exploit active transport mechanisms in lung epithelial cells. This strategy can improve the
absorption of drugs that typically have poor permeability across
lung membranes. Additionally, amino acid conjugation can
enhance the stability of certain drugs in the lung environment,
thereby protecting them from enzymatic degradation.
92]. This approach is particularly useful for protein
9 Personalized Medicine in Respiratory Drug Delivery
Customization of treatment for individual patients through pharmacogenomics. It investigates genetic variations in drugmetabolizing enzymes, specifically cytochrome P450 enzymes
(e.g., CYP2D6 and CYP3A4), which influence the metabolism of
inhaled corticosteroids and beta-2 agonists [
patients with the CYP2D6 poor metabolizer genotype may require
lower doses of salbutamol to minimize adverse effects. Furthermore, genetic variations in drug targets, such as beta-2 adrenergic
receptor (ADRB2) polymorphisms, affect the response to beta2 agonists. Patients with the Arg16 variant of ADRB2 may demonstrate a diminished response to albuterol compared to those with
the Gly16 variant [
genotyping patients using saliva samples to determine their
CYP2D6 genotype before prescribing inhaled corticosteroids, is
used to identify relevant polymorphisms [
95]. Pharmacogenomic testing, which includes
94]. For example,
96]. These
324 Pabbathi Shivakumar et al.
pharmacogenomic applications facilitate personalized treatments,
such as prescribing higher doses of formoterol to patients with the
Gly16 variant of ADRB2 to achieve optimal bronchodilation.
9.1 BiomarkerGuided Therapy
Biomarker-guided therapy for respiratory diseases employs diverse
biomarker types to inform treatment decisions and optimize
patient care. Molecular biomarkers, including eosinophil count,
fractional exhaled nitric oxide (FeNO), and serum periostin, play
pivotal roles in guiding therapy selection and predicting treatment
responses [
97]. For example, blood eosinophil counts are used to
guide anti-IL-5 therapy in severe asthma, with mepolizumab
recommended for patients with counts ≥300 cells/μL. Serum periostin levels exceeding 50 ng/mL can assist in identifying patients
with severe asthma who have a higher likelihood of responding to
lebrikizumab. Consistent monitoring of biomarkers, such as lung
function and symptom scores, facilitates treatment optimization. As
an illustration, inhaled corticosteroid doses may be adjusted based
on FeNO levels surpassing 50 ppb in patients with asthma.
Emerging biomarkers, such as exhaled breath condensate analysis,
present novel approaches for assessing airway inflammation, with
pH levels in condensates serving as indicators of airway acidity in
patients with COPD [
98]. The incorporation of multiple biomar-
kers into composite scores, combining molecular and clinical markers, has the potential to enhance the prediction of outcomes,
including exacerbation risk in asthma patients (Table
3).
The personalized medicine approach to respiratory drug delivery faces challenges in standardizing biomarker measurements,
developing point-of-care testing, and integrating pharmacogenomic data into clinical decision support systems. Large-scale clinical trials are needed to validate these approaches while addressing
cost-effectiveness and accessibility. Despite these challenges, incorporating pharmacogenomics and biomarker-guided therapy into
personalized respiratory medicine shows promise in improving
patient outcomes, reducing adverse effects, and optimizing
resource utilization in respiratory disease management.
10 Future Perspectives and Emerging Technologies
The field of respiratory drug delivery is advancing rapidly, driven by
innovative technologies aimed at enhancing therapeutic efficacy,
patient adherence, and addressing delivery challenges. Developments in nanotechnology, smart inhalers, and targeted delivery
systems have revolutionized respiratory medication administration.
Ongoing research on novel approaches promises more personalized
and efficient treatments for various pulmonary disorders, offering
opportunities to overcome current limitations and improve patient
outcomes.
Drug Delivery to the Respiratory System: Novel Approaches and Therapeutics 325
Table 3
Summary of key biomarkers used in personalized medicine for respiratory diseases
Associated
respiratory
Biomarker name
condition
Measurement method Clinical significance
Fractional exhaled
nitric oxide
(FeNO)
Blood eosinophil
count
Periostin Asthma Blood test Indicates Th
Alpha-1
antitrypsin
EGFR mutations Lung cancer Tissue biopsy, liquid
ALK
rearrangements
PD-L1 expression Lung cancer Immunohistochemistry Predicts response to immune
KRAS mutations Lung cancer Tissue biopsy, liquid
Sputum
neutrophil
count
Serum IgE levels Allergic asthma Blood test Predicts response to anti-IgE
Asthma Breath test Indicates eosinophilic airway
inflammation; guides
corticosteroid treatment
Asthma, COPD Blood test Predicts response to inhaled
corticosteroids and biologics
-high asthma; predicts
response to anti-IL-13 therapy
COPD Blood test Identifies alpha-1 antitrypsin
deficiency; guides augmentation
therapy
Predicts response to EGFR tyrosine
biopsy
Lung cancer Tissue biopsy,
immunohistochemistry
biopsy
Bronchiectasis Sputum analysis Indicates neutrophilic inflammation;
kinase inhibitors
Predicts response to ALK inhibitors
checkpoint inhibitors
Associated with poor prognosis;
guides treatment selection
guides antibiotic therapy
therapy (e.g., omalizumab)
2
IL-5 levels Eosinophilic
asthma
CFTR mutations Cystic fibrosis Genetic testing Confirms diagnosis; guides CFTR
10.1 3D-Printed Inhalers
Additive manufacturing techniques present significant potential for
the development of patient-specific inhaler designs, enabling precise control of device geometry and functionality [99].
Blood test Predicts response to anti-IL-5
therapy (e.g., mepolizumab)
modulator therapy selection
The integration of computational fluid dynamics (CFD) allows for the
optimization of airflow patterns and particle deposition within the
inhaler, thereby enhancing drug delivery efficiency. This approach
facilitates the customization of dose chamber volumes, mouthpiece
geometries, and actuation mechanisms to address individual patient
requirements and preferences. Moreover, 3D printing technology
offers the possibility of incorporating sensors and electronic
326 Pabbathi Shivakumar et al.
components, enabling smart inhaler functionality, such as dose
tracking, adherence monitoring, and real-time feedback
[100]. The rapid prototyping and iterative design capabilities inherent to additive manufacturing expedite the development of innovative inhaler concepts, while also enabling the production of
complex internal structures that enhance drug dispersion and minimize waste. Furthermore, this technology permits the creation of
lightweight ergonomic designs that enhance patient comfort and
usability.
Nevertheless, several challenges persist, including ensuring
material biocompatibility, long-term stability of printed components, scalability for mass production, and navigating regulatory
approval processes for novel manufacturing methods. To fully capitalize on the potential of 3D-printed inhalers, it is necessary to
develop specialized software tools for design optimization and
quality control, as well as conduct research on new materials that
satisfy both 3D printing requirements and pharmaceutical-grade
standards.
10.2 Artificial
Intelligence in Drug
Delivery
Artificial intelligence (AI) is transforming the field of drug delivery
through its diverse applications. Machine learning algorithms analyze extensive datasets to predict drug-excipient interactions and
stability, thereby enhancing formulation development efficiency.
Deep learning models optimize particle size distributions and aerodynamic properties, thus improving inhaled drug formulation performance. Natural language processing extracts insights from
scientific literature, facilitating the discovery of novel excipient
combinations. AI-driven pharmacokinetic/pharmacodynamic
modeling enables personalized dosing regimens, maximizing therapeutic efficacy while minimizing adverse effects [
101]. Reinforce-
ment learning algorithms optimize drug delivery device designs,
enhancing usability, and patient adherence. Computer vision techniques enable automated quality control in manufacturing processes, ensuring consistency in the appearance and performance of
drug products [
102]. AI-powered predictive maintenance systems
reduce equipment downtime and improve production efficiency.
Generative adversarial networks (GANs) simulate and predict the
long-term stability of drug formulations, potentially reducing the
need for extended stability studies [
103].
AI algorithms analyze
real-time patient data from smart inhalers, thereby enabling the
development of adaptive treatment strategies. Challenges include
ensuring data quality and representativeness, improving model
interpretability for regulatory compliance, integrating AI systems
with existing pharmaceutical processes, and mitigating potential
biases in the training data. The successful implementation of AI in
drug delivery necessitates interdisciplinary collaboration among
data scientists, pharmaceutical researchers, and regulatory experts.
Drug Delivery to the Respiratory System: Novel Approaches and Therapeutics 327
10.3 Organ-on-aChip Models
11 Conclusion
Organ-on-a-chip models are advanced microfluidic devices that
mimic human organs and provide a more physiologically relevant
environment for drug testing [104]. They incorporate multiple cell
types, 3D structures, and mechanical forces to replicate in vivo
conditions. These models enable high-throughput screening of
inhaled therapeutics, potentially reducing animal studies and offering opportunities for personalized medicine using patient-derived
cells. These models allow real-time monitoring of cellular
responses, investigation of organ-specific drug metabolism and
toxicity, and examination of drug-drug interactions. These results
support the development of novel drug delivery systems and
chronic exposure studies. Organ-on-a-chip models also facilitate
the creation of disease models for testing targeted therapies
105]. Challenges include the standardization of protocols, scal-
[
ability, and establishing correlations with in vivo results. They
require specialized imaging techniques, data analysis methods,
and interdisciplinary collaboration for the effective design and
interpretation of experiments (Table
4).
Recent advancements in respiratory drug delivery, including smart
inhalers, nanoparticle formulations, and targeted delivery systems,
have enhanced treatment efficacy and precision. The integration of
digital health solutions and artificial intelligence has facilitated
personalized medicine and real-time adherence monitoring,
thereby improving patient-care outcomes.
Notwithstanding these
advancements,
challenges persist in
areas such as drug stability, lung distribution, and overcoming
biological barriers. Furthermore, the cost-effectiveness and accessibility of these novel technologies require careful consideration to
ensure their widespread adoption.
Future r
esearch d
irections include the development of bioengineered lung tissue for drug testing and the exploration of novel
biomaterials for controlled release. As our understanding of respiratory diseases and their delivery mechanisms continues to evolve,
it is anticipated that more sophisticated treatment strategies will
emerge.
Significant progress
has been made in the field of respiratory
drug delivery, with the potential to substantially improve disease
management and patient outcomes globally.
328 Pabbathi Shivakumar et al.
Table 4
Emerging technologies in respiratory drug delivery and their potential applications
Potential impact on
Technology Description Development stage
respiratory drug delivery
Nanoparticle-
based delivery
Smart inhalers Inhalers equipped with sensors
3D-printed
inhalers
Acoustic droplet
ejection
Breath-actuated
dry powder
inhalers
Soft mist inhalers Devices generating a slow-
Par
ticle
engineering
Utilization of engineered
nanoparticles for drug
encapsulation and delivery
and connectivity for
adherence and technique
monitoring
Customized inhaler devices
manufactured using 3D
printing technology
Precise droplet formation
utilizing sound waves for
controlled inhalation
Inhalers that dispense
medication upon proper
inhalation
moving mist for enhanced
lung deposition
Design of par
aerodynamic properties
ticles with specific
Clinical trials Enhanced drug solubility,
targeted delivery,
improved lung
deposition
Early
commercialization
Preclinical research Personalized devices,
Preclinical research Enhanced dose accuracy,
Late-stage
development
Early
commercialization
Ongoing research
and development
Improved patient
adherence, real-time data
provision for healthcare
providers
expedited prototyping
for drug development
potential for complex
formulations
Reduced reliance on
patient coordination,
improved dr
Extended spray duration,
decreased oropharyngeal
deposition
Enhanced deep lung
penetration, controlled
release profiles
ug delivery
Exhalation
delivery
systems
Vibrating mesh
technology
Microfluidic
nebulizers
Devices utilizing exhalation for
targeted drug delivery to nasal
areas
Ultra-fine mesh vibration for
aerosol generation
Precise droplet generation
utilizing microfluidic
References
1. Sheng G, Tian N, Sun Z, Duan H, Chu H
(2022) Advances in therapeutic nanodrug
delivery systems for infectious lung diseases:
a review. Acta Materia Medica 1(3):
10.15212/amm-2022-0019
channels
Clinical trials Improved delivery to
and nasal
potential for CNS
targeting
Early
commercialization
Preclinical research Unifor
2. He S, Xiong K, Fu Y, Gao H, Gui J, Chen M
(2022) A roadmap to pulmonary delivery
strategies for the treatment of infectious
lung diseases. J Nanobiotechnol 20(1) Springer Science Business Media LLC.
Efficient nebulization,
potential for broader
formulation range
potential for
combination therapies
regions,
m particle size,
sinus